$69 postpage LB

Creso Pharma (ASX:CPH) Delivers 2nd cannaQIX® shipment in Africa, Shares up ~4%

  • January 12, 2021 03:02 PM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2212 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Creso Pharma (ASX:CPH) Delivers 2nd cannaQIX® shipment in Africa, Shares up ~4%

Summary

  • Nedlands-headquartered Creso Pharma delivers the 2nd shipment of its cannaQIX® products to Pharma Dynamics in South Africa.
  • With a second purchase order (PO) and delivery, Creso adds A$320K to its growing revenue.
  • The cannabis player is looking forward to further growth in Africa and other territories with Pharma Dynamics.
Gold MTF non-AMP

ASX-listed cannabis player Creso Pharma Limited (ASX:CPH, FRA:1X8) announced that the Company had completed all the procedures necessary to import and export cannaQIX® shipment. Further, the Company stated that the second shipment of cannaQIX® products had been delivered to Pharma Dynamics South Africa, Lupin International’s (NYSE:LUPIN) subsidiary.

After the announcement, CPH shares were up on the ASX and were trading at A$0.240, up by 4.347% at AEDT 2:51 PM. The market capitalisation of the Company stood at A$162.15 million.

 ©Kalkine Group 2020

Growing revenue profile of Creso Pharma with the second PO

Creso Pharma stated that the delivery of the second shipment follows the receipt from Pharma Dynamics in October 2020, which is valued at CHF220,000 (almost A$320K). The amount has been banked and adds to the growing revenue profile of Creso Pharma.

The second PO delivery follows the launch of Creso Pharma into the market of South Africa with Pharma Dynamics.

Notably, during the second quarter of 2020, Pharma Dynamics launched cannaQIX® regular products and is marketing cannaQIX® with the brand name- Cannamics.

ALSO READ: Creso Pharma (ASX:CPH) gains ground in Canadian Cannabis Market

Pharma Dynamics to extend distribution of hemp-based products of CPH

Pharma Dynamics has a developing range of over-the-counter (OTC) products, including treatments for cold and flu, allergy, and digestion, along with immunity booster wellness products. Pharma Dynamics’ products are recommended and prescribed by leading physicians and pharmacists all over the country.

Pharma Dynamics distributes the hemp-based products of Creso Pharma across South Africa.

  • Pharma Dynamics is planning to extend the distribution to Angola, Botswana, Lesotho, Mozambique, Namibia, Swaziland, Uganda, and Zimbabwe.
  • CPH is assured that in the upcoming period, more opportunities will materialise in Africa.
  • Besides, the Company continues to work in partnership with Pharma Dynamics for establishing a wider footprint across Africa.
  • Creso anticipates PO’s to increase in volume and size in the future.

cannaQIX® in a nutshell

cannaQIX® is a range of CBD hemp oil-based nutraceuticals developed by Creso Pharma.

Source: Shutterstock

  • cannaQIX® comprises a broad spectrum of hemp oil extracts (organic) with cannabidiol (CBD) that intends to manage stress and support nervous and mental functions.
  • The product has been developed by using standards of Good Manufacturing Practice (GMP).
  • The strength and formulation of the product allow precise dosage control.
  • The cannaQIX® lozenges are more palatable as compared to already available oils in the market.

Creso Pharma is confident that its product will be well-received by South African consumers.

Commercial Director of Creso Pharma Jorge Wernli, commented:

INTERESTING READ: MORE Act to boost Creso's hopes to foray into The US Cannabis Market

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK